The US Food and Drug Administration doubled the size of the 2021 class of novel cancer therapies with the recent approval of AVEO Pharmaceuticals, Inc.’s Fotivda (tivozanib) and Oncopeptides AB’s Pepaxto (melphalan flufenamide).
Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
